Windrose Consulting Group

Windrose Consulting Group are pleased to welcome our latest hire, Jose M. Galan, PhD, to our US office as a Partner. Jose brings over 15 years of experience advising pharmaceutical companies on a broad range of pricing and market access engagements. Before joining Windrose Consulting Group, Jose was a Managing Principal at IQVIA Value & Access Strategy in New York. During his time at IQVIA, he led over 400 consulting engagements. He has also acted as a Managing Director at ClearView Healthcare Partners in New York and as a Director at Campbell Alliance, where he consolidated his expertise in oncology and ultra rare diseases. Jose holds a PhD in Cellular, Molecular, Structural and Genetic Studies from Columbia University Vagelos College of Physicians and Surgeons. Read more at our website https://lnkd.in/ekDFADUw #newhire #windrose #team #partner

With less than a year to go until the launch of the Joint Clinical Assessment (JCA) in January 2025, its successful implementation relies on the readiness of each EU market and their willingness to incorporate the JCA into current HTA processes. In this article, written by Katherine Yang and Kate Gilbert, PhD, they look at how the SUSTAIN-HTA project aiming to bridge the gap between individual markets, the JCA and wider EU HTA updates, as well as the implications for manufacturers. Read the full article at our website: https://lnkd.in/ecwPE9SA #windrose #hta #jca #eu

The recent FDA approval of two groundbreaking gene therapies for sickle cell disease —Casgevy and Lyfgenia—marks a significant milestone in the field, offering life-changing treatments for patients suffering from this debilitating genetic disorder. These developments also raise crucial considerations for equitable patient access, as gene therapy manufacturers must navigate complex regulatory pathways, pricing & reimbursement challenges, and distribution logistics. In this article, written by Noah Blase and Steven Xiteng Lin, they explore the recent and upcoming approvals of gene therapies, along with the launch of the CMS's CGT Access Model, marking a pivotal moment in the gene therapy landscape. These advancements offer promising treatments for diseases with high unmet needs while also introducing a complex array of market access opportunities and challenges for manufacturers. Read the full article at our website here: https://lnkd.in/eM-6XbX9

On January 5th, 2024, the FDA allowed Florida the ability to import prescription drugs from Canada on a provisional basis. While many states have filed for similar permissions, the ruling marks a significant deviation from past precedent and may lead to reduced prescription drug costs in the US. Florida estimates the program will save ~$183M in prescription drug spending in the first year following implementation. In this article, written by Rohit Palekar and Janani Gurumurthy, they explore the challenges and pushback this new decision has, as well as the anticipated impact on the US healthcare system and manufacturers. Read the full article at our website here: https://lnkd.in/edVnA9De

Register today for “Developing a Successful Biopharmaceutical Pricing & Market Access Strategy”, our executive education programme, which is a collaboration between Windrose Consulting Group and the University of Cambridge MPhil in Bioscience Enterprise (MBE). The virtual course will be run over 7 sessions, on Thursdays from the 23rd of May, until the 11th of July 2024 (1pm – 3 pm BST). The course is run by industry leaders, including Matt Storer, Zameer Merchant, Anaïs Frappé, Andrew Walker, Professor Seamus Higson, Dr David Hampton, and Lisa (Elizabeth) Hall CBE. Our course alumni have great feedback, some of which can be read at our website, including the full quote from Pascal Dammeyer. All course information can be found at our website here: https://lnkd.in/dXBNx7Qx #cambridgeuniversity #windrose #pricingstrategy #training #course

A new, non-contractual voluntary agreement has been implemented in the UK since the start of January 2024 and is set to run for 5 years, between the Department of Health and Social Care (DHSC)*, NHS England, and the Association of British Pharmaceutical Industry (ABPI). In this article Steven Xiteng Lin and Myrto Vouga review the new Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG). They explore this replacement of the older 2019-2023 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which aims to manage spending on branded medicines, support the attractiveness of the UK pharmaceutical market, and promote financial sustainability for the NHS. Read the full article at our website here: https://lnkd.in/eHSGSy6V #NHS #Windrose #NICE #Britishpharma

Register now for “Developing a Successful Biopharmaceutical Pricing & Market Access Strategy”, our executive education programme, which is a collaboration between Windrose Consulting Group and the University of Cambridge MPhil in Bioscience Enterprise (MBE). The virtual course will be run over 7 sessions, on Thursdays from the 23rd of May, until the 11th of July 2024 (1pm – 3 pm BST). The course is run by industry leaders, including Matt Storer, Zameer Merchant, Anaïs Frappé, Andrew Walker, Professor Seamus Higson, Dr David Hampton, and Lisa (Elizabeth) Hall CBE. Our course alumni have great feedback, some of which can be read at our website, including the full quote from Amilcar Azamar, Ph.D. All course information can be found at our website here: https://lnkd.in/e_EW3mmu #cambridgeuniversity #windrose #pricingstrategy #training #course

Windrose are thrilled to announce four promotions in our team. Ioana Vitan has been promoted to Senior Analyst; William Henri Noumba Um has been promoted to Consultant; and both Anjalina Mitra and Stacey McDonald have both been promoted to Senior Consultant roles. All the team have consistently delivered high-quality work to our clients and are respected members of the Windrose Consulting Group. We are happy to share these well-deserved promotions for Ioana, William, Anjalina and Stacey. #team #windrose #promotions See this story and more of our news at https://lnkd.in/eMCrdAKV

Sign up now for “Developing a Successful Biopharmaceutical Pricing & Market Access Strategy”, our executive education programme, which is a collaboration between Windrose Consulting Group and the University of Cambridge MPhil in Bioscience Enterprise (MBE). The virtual course will be run over 7 sessions, on Thursdays from the 23rd of May, until the 11th of July 2024 (1pm – 3 pm BST). The course is run by industry leaders, including Matt Storer, Zameer Merchant, Anaïs Frappé, Andrew Walker, Professor Seamus Higson, Dr David Hampton, and Lisa (Elizabeth) Hall CBE. Our course alumni have great feedback, some of which can be read at our website, including the full quote from Ahmed Eladawi, MBA,PMP,CPM. All course information can be found at our website here:   https://lnkd.in/eaccgmuX #cambridgeuniversity #windrose #pricingstrategy #training #course

Registration is now open for “Developing a Successful Biopharmaceutical Pricing & Market Access Strategy”, our executive education programme, which is a collaboration between Windrose Consulting Group and the University of Cambridge MPhil in Bioscience Enterprise (MBE). The virtual course will be run over 7 sessions, on Thursdays from the 23rd of May, until the 11th of July 2024 (1pm – 3 pm BST). The course is a blend of lectures, case studies and practical exercises. We believe in an interactive approach, encouraging group discussion and exploring real-world situations. The aim is not just to provide the theory, but help you understand how to apply it within your role or future career.  The course is run by industry leaders, including Matt Storer, Zameer Merchant, Anaïs Frappé, Andrew Walker, Professor Seamus Higson, Dr David Hampton, Lisa (Elizabeth) Hall CBE.   All course information can be found on our course page here: https://lnkd.in/eT98a6xh #cambridgeuniversity #windrose #pricingstrategy #training #course